{
    "clinical_study": {
        "@rank": "127806", 
        "arm_group": [
            {
                "arm_group_label": "SOF/LDV (treatment naive)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive participants will receive SOF/LDV for 12 weeks."
            }, 
            {
                "arm_group_label": "SOF/LDV+RBV (treatment naive)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive participants will receive SOF/LDV plus RBV for 12 weeks."
            }, 
            {
                "arm_group_label": "SOF/LDV (treatment experienced)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-experienced participants will receive SOF/LDV for 12 weeks."
            }, 
            {
                "arm_group_label": "SOF/LDV+RBV (treatment experienced)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-experienced participants will receive SOF/LDV plus RBV for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV)\n      fixed-dose combination (FDC) with or without ribavirin (RBV) in treatment-naive or\n      treatment-experienced Japanese participants with chronic genotype 1 HCV infection at\n      approximately 20 sites in Japan. Participants receive 12 weeks of treatment and continue\n      assessments during a 24-week follow-up period."
        }, 
        "brief_title": "Efficacy and Safety of Sofosbuvir/Ledipasvir \u00b1 Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HCV Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight \u2265 40 kg\n\n          -  HCV RNA \u2265 10^5 IU/mL at screening\n\n        Exclusion Criteria:\n\n          -  Current or prior history of any clinically-significant illness (other than HCV)\n\n          -  Pregnant or nursing female or male with pregnant female partner\n\n          -  Chronic liver disease of a non-HCV etiology\n\n          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975675", 
            "org_study_id": "GS-US-337-0113"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SOF/LDV (treatment naive)", 
                    "SOF/LDV+RBV (treatment naive)", 
                    "SOF/LDV (treatment experienced)", 
                    "SOF/LDV+RBV (treatment experienced)"
                ], 
                "description": "SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily", 
                "intervention_name": "SOF/LDV", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "GS-5885"
                ]
            }, 
            {
                "arm_group_label": [
                    "SOF/LDV+RBV (treatment naive)", 
                    "SOF/LDV+RBV (treatment experienced)"
                ], 
                "description": "RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\u2264 60 kg = 600 mg, > 60 kg to \u2264 80 kg = 800 mg, and \u2265 80 kg = 1000 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug", 
                "other_name": "Copegus\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ichikawa", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "272-8516"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kurume", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "830-0011"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ogaki", 
                        "country": "Japan", 
                        "state": "Gifu", 
                        "zip": "503-0864"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "060-8648"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nishinomiya", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "663-8501"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsumoto", 
                        "country": "Japan", 
                        "state": "Nagano", 
                        "zip": "390-8621"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omura", 
                        "country": "Japan", 
                        "state": "Nagasaki", 
                        "zip": "856-8562"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "565-0871"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izunokuni", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "410-2295"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "101-8643"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itabashi-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "173-8610"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Musashino", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "180-8610"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "162-8566"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kofu", 
                        "country": "Japan", 
                        "state": "Yamanashi", 
                        "zip": "400-0027"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akita", 
                        "country": "Japan", 
                        "zip": "010-0933"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "260-0856"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gifu", 
                        "country": "Japan", 
                        "zip": "500-8513"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-8558"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamagata", 
                        "country": "Japan", 
                        "zip": "990-9585"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination \u00b1 Ribavirin in Treatment-Na\u00efve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Steven Knox", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study medication.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Week 12"
            }, 
            {
                "measure": "Proportion of participants who permanently discontinue study drug due to an adverse event", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Weeks 4 and 24"
            }, 
            {
                "description": "Viral breakthrough is defined as HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.", 
                "measure": "Proportion of participants experiencing viral breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "Viral relapse is defined as HCV RNA \u2265 LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.", 
                "measure": "Proportion of participants experiencing viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Week 12 to post-treatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}